Neuropathic pain:
Neuropathic pain affects around 10% of the world’s population – about 800 million people. It is the largest unmet need in pain treatment globally, with a global annual market of US$9.1 billion*.
It is most commonly caused by chemotherapy, diabetes, surgery, infections like shingles, and physical trauma including car accidents.
Current treatments are suboptimal and have a host of detrimental side effects. Most current drugs are out of patent, and there’s a significant lack of new candidates in the pipeline.
Introducing
RM191A: A breakthrough topical treatment for neuropathic pain
We recently completed a phase 2a clinical trial which evaluated RM191A gel in patients with chronic, severe, treatment-resistant peripheral neuropathic pain.
RM191A (BioCuplex™) in topical formulation demonstrated a compelling efficacy signal and an excellent safety profile. It had no side‑effects attributable to RM191A, was used safely with common pain medications, and was non‑addictive.
Results of this study have been published in Frontiers in Pain Research, 2026.
*https://www.grandviewresearch.com/industry-analysis/neuropathic-pain-market-report accessed Nov 2026